GlassScriptPhysician profile
John C Hummel
NPI 1609860873
$1,752.41
in general payments reported to CMS, 2019-2025
13 companies · $454 in 2025
The $454 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151 · 2020: $64.49 · 2021: $99.35 · 2022: $596 · 2023: $202 · 2024: $186 · 2025: $454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $816 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $816.31 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $778.21 | 2019-2025 | Clareon Panoptix Pro, Argos, Clareon |
| Rxsight INC | $334.34 | 2022-2024 | Rxsight Injector Cartridge, Rxsight Injector Handpiece, Rxsight Contact Lens |
| Bausch & Lomb Americas INC. | $160.74 | 2023-2025 | Envista Envy Iol, Vyzulta, Lotemax Sm |
| Johnson & Johnson Surgical Vision, INC. | $145.25 | 2025 | Catalys System |
| Abbvie INC. | $126.98 | 2022-2024 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $38.71 | 2020-2021 | |
| Sun Pharmaceutical Industries INC. | $38.40 | 2022 | |
| Johnson & Johnson Vision Care, INC. | $34.84 | 2022 | |
| Glaukos Corporation | $25.89 | 2024 | Idose |
| Dompe US, INC. | $21.97 | 2024 | Oxervate |
| Ocular Therapeutix, INC. | $16.49 | 2021 | |
| Harrow Eye, LLC | $15.97 | 2024 | Vevye |
| Katena Products, INC. (Dba Corza Medical) | $14.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hummel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.